论文部分内容阅读
目的观察替吉奥(S-1)联合奥沙利铂(oxaliplatin,L-OHP)方案治疗晚期胃癌的近期疗效及毒性反应。方法 23例均经病理组织学确诊为晚期胃腺癌,且手术不可切除或术后复发、转移胃癌。替吉奥80mg/m2/d,第1-14d,早晚饭后口服各1次;L-OHP130mg/m2加入5%葡萄糖液250ml中静脉滴注2h,第1 d,每3-4周为1个周期,完成2周期化疗后评价疗效及毒性反应。结果 23例患者有1例CR(4.3%),12例PR(52.2%),6例SD(26.1%),4例PD(17.4%),有效率(CR+PR)56.5%,疾病控制率(CR+PR+SD)82.6%。中位疾病进展时间(time to progression,TTP)5.8个月。毒副反应轻微,主要为胃肠道反应、骨髓抑制及外周神经毒性反应,但主要为Ⅰ-Ⅱ度。结论替吉奥联合奥沙利铂方案治疗晚期胃癌有较好疗效,毒副反应轻微,患者耐受性好,可作为晚期胃癌化疗方案临床应用推广。
Objective To observe the short-term curative effect and toxicity of late treatment of advanced gastric cancer with S-1 combined with oxaliplatin (L-OHP) regimen. Methods 23 cases were diagnosed as advanced gastric adenocarcinoma by histopathology, and the surgery was unresectable or recurrence, gastric cancer metastasis. Tigao 80mg / m2 / d, 1-14d, morning and evening after oral administration of 1; L-OHP130mg / m2 added 5% glucose 250ml intravenous infusion of 2h, 1 d, every 3-4 weeks for the 1 A cycle, after completion of 2 cycles of chemotherapy to evaluate the efficacy and toxicity. Results There were 1 case of CR (4.3%), 12 cases of PR (52.2%), 6 cases of SD (26.1%), 4 cases of PD (17.4%) and effective rate (CR + PR) of 56% (CR + PR + SD) 82.6%. Median disease progression time (TTP) 5.8 months. Toxicity was mild, mainly gastrointestinal reactions, bone marrow suppression and peripheral neurotoxic reactions, but mainly Ⅰ-Ⅱ degrees. CONCLUSION: The combination of TEGO and oxaliplatin is effective in treating advanced gastric cancer with mild toxicity and good tolerability. It can be used as a clinical application of advanced gastric cancer chemotherapy.